EpiCast Report: Gram-Negative Bacterial Pneumonia - Epidemiology Forecast to 2022

NEW YORK, Oct. 21, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

EpiCast Report: Gram-Negative Bacterial Pneumonia - Epidemiology Forecast to 2022

http://www.reportlinker.com/p01816890/EpiCast-Report-Gram-Negative-Bacterial-Pneumonia---Epidemiology-Forecast-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

EpiCast Report: Gram-Negative Bacterial Pneumonia - Epidemiology Forecast to 2022

Summary

Chronic diseases such as asthma, chronic obstructive pulmonary disease, and heart disease increase the risk of developing pneumonia. Elderly patients (65 years and older) have twice the incidence of hospital-acquired pneumonia compared with the adult population. Additionally, tobacco smoking has been identified as a cause of pneumonia.

In 2012, the 6MM (US, France, Germany, Italy, Spain, UK) had 4,184,449 incident cases of CAP, with 82% of that occurring in the US. By 2022, GlobalData epidemiologists forecast there will be 4,670,664 incident cases of CAP in the 6MM. In Japan, there were 40,043 cases of CAP and HAP with an annual growth rate (AGR) of 3.78%.

These 7MM are important markets for CAP and HAP during the next 10 years because these countries have a growing older population. Pneumonia incidence differs between countries, possibly due to socioeconomic factors, differences in infectious disease reporting, and heterogeneity of diagnostics. From a public health perspective, effective prevention and treatment measures should be in place to avoid disease transmission and reduce the incidence of pneumonia.

Scope

- The Gram-Negative Bacterial Pneumonia EpiCast Report provides an overview of the risk factors and epidemiological trends for pneumonia, with a focus on gram-negative bacteria, in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of incident cases of community-acquired pneumonia (CAP) segmented by sex and age (in five-year increments beginning at 0 years and ending at =85 years), incident cases of hospital-acquired pneumonia (HAP), and incident cases of ventilator-associated pneumonia (VAP). Incident HAP cases are further segmented by causative pathogens (Acinetobacter, Escherichia coli, Klebsiella, and Pseudomonas) and antibiotic resistance in these markets.- The gram-negative bacterial pneumonia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global pneumonia market. - Quantify patient populations in the global pneumonia market to improve product design, pricing, and launch plans. - Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for pneumonia therapeutics in each of the markets covered.1 Table of Contents1 Table of Contents 41.1 List of Tables 51.2 List of Figures 62 Introduction 72.1 Catalyst 72.2 Related Reports 72.3 Upcoming Reports 73 Epidemiology 83.1 Disease Background 83.2 Risk Factors and Comorbidities 93.2.1 Chronic Diseases Increase the Risk of Developing Pneumonia 93.2.2 Immunosuppressive Diseases Increase Risk of Pneumonia and Heightens Mortality 103.2.3 Adults are Less at Risk for HAP Compared with Elderly Patients and Children 113.2.4 Current Smokers Have 1.88 Greater Odds of Developing CAP 113.3 Forecast Methodology 123.3.1 Sources Used 133.3.2 Sources Not Used 203.3.3 Forecast Assumptions and Methods 203.4 Epidemiological Forecast of Pneumonia (2012-2022) 263.4.1 US 263.4.2 5EU 303.4.3 Japan 393.5 Discussion 433.5.1 Epidemiological Forecast Insight 433.5.2 Limitations of the Analysis 433.5.3 Strengths of the Analysis 444 Appendix 454.1 Bibliography 454.2 About the Authors 494.2.1 Epidemiologists 494.2.2 Reviewers 494.2.3 Global Director of Epidemiology and Health Policy 514.2.4 Global Head of Healthcare 524.3 About GlobalData 534.4 About EpiCast 534.5 Disclaimer 53

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for Pneumonia 9

Table 2: Sources of CAP Incidence Data Used in the Epidemiology Forecast 12

Table 3: US, Incident Cases of Pneumonia by Site of Acquisition, All Ages, Both Sexes, N, 2012-2022 26

Table 4: US, Incident Cases of CAP, N, by Age, Sex, N (Row %), 2012 27

Table 5: US, Incident Cases of Gram-Negative Bacterial Pneumonia, by Pathogen and Site of Acquisition, All Ages, Both Sexes, N (Pathogen-Specific %), 2012 28

Table 6: US, Incident Cases of Gram-Negative Bacterial Pneumonia, by Pathogen and Multidrug and Carbapenem Resistance, N (Antibiotic-Resistant Pathogen-Specific %), 2012 29

Table 7: 5EU, Incident Cases of CAP, All Ages, Both Sexes, N, Select Years, 2012-2022 30

Table 8: 5EU, Incident Cases of CAP, Both Sexes, by Age, N (Row %), 2012 31

Table 9: 5EU, Incident Cases of CAP, All Ages, by Sex, N (Row %), 2012 33

Table 10: 5EU, Incident Cases of HAP, All Ages, Both Sexes, N, Select Years, 2012-2022 34

Table 11: 5EU, Incident Cases of VAP, All Ages, Both Sexes, N, Select Years, 2012-2022 35

Table 12: 5EU, Incident Cases of Gram-Negative Bacterial CAP, by Pathogen, N (Pathogen-Specific %), 2012 36

Table 13: 5EU, Incident Cases of Gram-Negative Bacterial HAP, by Pathogen, N (Pathogen-Specific %), 2012 37

Table 14: 5EU, Incident Cases of Gram-Negative Bacterial HAP, by Pathogen and Multidrug/Carbapenem Resistance, N (Antibiotic-Resistant Pathogen-Specific %), 2012 38

Table 15: Japan, Incident Cases of CAP and HAP, N, Select Years, 2012-2022 39

Table 16: Japan, Incident Cases of CAP and HAP, by Age, Sex, N (Row %), 2012 40

Table 17: Japan, Incident Cases of Gram-Negative Bacterial Pneumonia, by Pathogen, N (Pathogen-Specific %), 2012 41

Table 18: Japan, Incident Cases of Gram-Negative Bacterial Pneumonia, by Pathogen and Antibiotic Resistance, N and Percentage of Pathogen-Specific Cases, 2012 42

1.2 List of FiguresFigure 1: US, Incident Cases of Pneumonia by Site of Acquisition, All Ages, Both Sexes, N, 2012-2022 27Figure 2: US, Incident Cases of CAP, N, by Age, Sex, N, 2012 28Figure 3: US, Incident Cases of Gram-Negative Bacterial Pneumonia, by Pathogen and Site of Acquisition, All Ages, Both Sexes, N, 2012 29Figure 4: 5EU, Incident Cases of CAP, All Ages, Both Sexes, N, Select Years, 2012-2022 31Figure 5: 5EU, Incident Cases of CAP, Both Sexes, by Age, N (Row %), 2012 32Figure 6: 5EU, Incident Cases of CAP, All Ages, by Sex, N, 2012 33Figure 7: 5EU, Incident Cases of HAP, All Ages, Both Sexes, N, Select Years, 2012-2022 34Figure 8: 5EU, Incident Cases of VAP, All Ages, Both Sexes, N, Select Years, 2012-2022 35Figure 9: 5EU, Incident Cases of Gram-Negative Bacterial CAP, by Pathogen, N, 2012 36Figure 10: 5EU, Incident Cases of Gram-Negative Bacterial HAP, by Pathogen, N, 2012 37Figure 11: Japan, Incident Cases of CAP and HAP, N, Select Years, 2012-2022 39Figure 12: Japan, Incident Cases of CAP and HAP, by Age, Sex, N, 2012 40Figure 13: Japan, Incident Cases of Gram-Negative Bacterial Pneumonia, by Pathogen, N, 2012 41

To order this report: EpiCast Report: Gram-Negative Bacterial Pneumonia - Epidemiology Forecast to 2022 http://www.reportlinker.com/p01816890/EpiCast-Report-Gram-Negative-Bacterial-Pneumonia---Epidemiology-Forecast-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

 Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker